Copyright Notice
Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
Bookshelf ID: NBK591117PMID: 37094050
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 1474034-05-3
Drug Levels and Effects
Summary of Use during Lactation
No information is available on the clinical use of omaveloxolone during breastfeeding. Because it is 97% protein bound, exposure of the breastfed infant is likely to be low. Until more data become available, omaveloxolone should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Substance Identification
Substance Name
Omaveloxolone
CAS Registry Number
1474034-05-3
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- PubChem SubstanceRelated PubChem Substances
- 4,4,6a,6b,11,12,14b-Heptamethyl-16-oxo-1,2,3,4,4a,5,6,6a,6b,7,8,9,10,11,12,12a,14a,14b-octa-deca-hydro-12b,8a-(epoxy-methano)-picen-3-yl acetate.[Acta Crystallogr Sect E Struct...]4,4,6a,6b,11,12,14b-Heptamethyl-16-oxo-1,2,3,4,4a,5,6,6a,6b,7,8,9,10,11,12,12a,14a,14b-octa-deca-hydro-12b,8a-(epoxy-methano)-picen-3-yl acetate.Nisar M, Ali S, Tahir MN, Ahmad B, Hameed S. Acta Crystallogr Sect E Struct Rep Online. 2013 Apr 1; 69(Pt 4):o573. Epub 2013 Mar 23.
- Semisynthetic ursolic acid fluorolactone derivatives inhibit growth with induction of p21(waf1) and induce apoptosis with upregulation of NOXA and downregulation of c-FLIP in cancer cells.[ChemMedChem. 2012]Semisynthetic ursolic acid fluorolactone derivatives inhibit growth with induction of p21(waf1) and induce apoptosis with upregulation of NOXA and downregulation of c-FLIP in cancer cells.Leal AS, Wang R, Salvador JA, Jing Y. ChemMedChem. 2012 Sep; 7(9):1635-46. Epub 2012 Jul 16.
- Review Eravacycline.[Drugs and Lactation Database (...]Review Eravacycline.. Drugs and Lactation Database (LactMed®). 2006
- Review Omadacycline.[Drugs and Lactation Database (...]Review Omadacycline.. Drugs and Lactation Database (LactMed®). 2006
- Review Minocycline.[Drugs and Lactation Database (...]Review Minocycline.. Drugs and Lactation Database (LactMed®). 2006
- Omaveloxolone - Drugs and Lactation Database (LactMed®)Omaveloxolone - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...